JAZZ PHARMACEUTICALS PLC (1JAZZ.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:1JAZZ - IE00B4Q5ZN47 - Common Stock
1JAZZ.MI Key Statistics, Chart & Performance
The current stock price of 1JAZZ.MI is 153.95 EUR.
1JAZZ.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1SAN.MI | SANOFI | 11.36 | 210.22B | ||
| SNW.DE | SANOFI | 11.34 | 209.38B | ||
| SAN.PA | SANOFI | 11.37 | 210.44B | ||
| MRK.DE | MERCK KGAA | 13.53 | 50.17B | ||
| UCB.BR | UCB SA | 36.78 | 45.92B | ||
| UNC.DE | UCB SA | 34.83 | 43.49B | ||
| 1BAYN.MI | BAYER AG-REG | 5.75 | 30.18B | ||
| BAYN.DE | BAYER AG-REG | 5.77 | 30.29B | ||
| IPN.PA | IPSEN | 12.47 | 10.74B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 25.74 | 10.60B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 97.96 | 9.07B | ||
| VIRP.PA | VIRBAC SA | 20.85 | 3.03B |
Related stock screener links
About 1JAZZ.MI
Company Profile
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Company Info
JAZZ PHARMACEUTICALS PLC
Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4
DUBLIN DUBLIN IE
Employees: 2800
Phone: 35316347800
JAZZ PHARMACEUTICALS PLC / 1JAZZ.MI FAQ
What does JAZZ PHARMACEUTICALS PLC do?
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
What is the stock price of JAZZ PHARMACEUTICALS PLC today?
The current stock price of 1JAZZ.MI is 153.95 EUR.
Does 1JAZZ stock pay dividends?
1JAZZ.MI does not pay a dividend.
How is the ChartMill rating for JAZZ PHARMACEUTICALS PLC?
1JAZZ.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for JAZZ PHARMACEUTICALS PLC?
JAZZ PHARMACEUTICALS PLC (1JAZZ.MI) operates in the Health Care sector and the Pharmaceuticals industry.
Should I buy 1JAZZ stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1JAZZ.MI.
Can you provide the market cap for JAZZ PHARMACEUTICALS PLC?
JAZZ PHARMACEUTICALS PLC (1JAZZ.MI) has a market capitalization of 9.34B EUR. This makes 1JAZZ.MI a Mid Cap stock.
1JAZZ.MI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 1JAZZ.MI.
1JAZZ.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1JAZZ.MI. 1JAZZ.MI may be in some trouble as it scores bad on both profitability and health.
1JAZZ.MI Financial Highlights
Over the last trailing twelve months 1JAZZ.MI reported a non-GAAP Earnings per Share(EPS) of 7.07. The EPS decreased by -58.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| Debt/Equity | 1.09 |
1JAZZ.MI Forecast & Estimates
25 analysts have analysed 1JAZZ.MI and the average price target is 167.41 EUR. This implies a price increase of 8.74% is expected in the next year compared to the current price of 153.95.
For the next year, analysts expect an EPS growth of -74.64% and a revenue growth 4.41% for 1JAZZ.MI